Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

PURPOSE: High-dose interleukin-2 (IL-2) induces responses in 15% to 20% of patients with advanced melanoma; 5% to 8% are durable complete responses (CRs). The HLA-A2–restricted, modified gp100 peptide (210M) induces T-cell immunity in vivo and has little antitumor activity but, combined with high-do...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sosman, Jeffrey A., Carrillo, Carole, Urba, Walter J., Flaherty, Lawrence, Atkins, Michael B., Clark, Joseph I., Dutcher, Janet, Margolin, Kim A., Mier, James, Gollob, Jarod, Kirkwood, John M., Panka, David J., Crosby, Nancy A., O’Boyle, Kevin, LaFleur, Bonnie, Ernstoff, Marc S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3724516/
https://ncbi.nlm.nih.gov/pubmed/18467720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.13.3165
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados